dsm-firmenich announced FDA approval of bemotrizinol (PARSOL® Shield), the first new sunscreen active ingredient approved in the U.S. in over 25 years. This approval under modern safety guidelines marks a major advancement in sun protection, offering broad-spectrum UV defense with excellent safety and tolerability. It allows manufacturers to create next-generation, lightweight, and photostable sunscreens, addressing consumer needs like skin cancer risk reduction and photoaging prevention. Already approved globally, PARSOL® Shield supports sustainable and efficient sunscreen formulations, enhancing public skin health and innovation in the U.S. market.
The US government has identified 16 minerals it produces none of, making the country 100% reliant on imports for these critical materials, which poses national security and economic risks. Financial expert Jim Rickards highlights this dependency, esp...
Anthropic's advanced AI model, Mythos, conducted a full security audit of the Zcash protocol at Shielded Labs's request and found no new critical vulnerabilities as of June 12, 2026. This follows a recent crisis caused by a critical bug in the Orchar...
Crypto markets experienced $186 million in liquidations over 24 hours due to volatile price moves, with losses split between long and short positions. Bitcoin saw $34.97 million liquidated and Ethereum $24.65 million, reflecting market uncertainty. M...
The US and Iran are expected to finalize a peace agreement within 24 hours, potentially ending over three months of conflict that disrupted global energy supplies and raised gasoline prices. Pakistan's Prime Minister Shehbaz Sharif announced preparat...
Genmab announced positive Phase 2 and Phase 1b/2 trial results for epcoritamab, a T-cell engaging antibody, in elderly patients with newly diagnosed diffuse large B-cell lymphoma (DLBCL) who are ineligible for standard chemotherapy. The Phase 2 trial...
